Not checked for notices yet.

Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model

C. Joaquín Cáceres, Stivalis Cardenas-Garcia, Silvia Carnaccini and 4 more

Scientific Reports · 2021

doi:10.1038/s41598-021-89013-w

References 43

1.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
2.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
3.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
4.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
5.
Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor · 2016
Corrected
6.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
7.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020
No notice
8.
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro · 2020
No notice
9.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
10.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
11.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
12.
Immunogenicity of a DNA vaccine candidate for COVID-19 · 2020
No notice
13.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
14.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
15.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
16.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
17.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
18.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
19.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
20.
Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development · 2020
No notice
21.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
22.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
23.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
24.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
25.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
26.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
27.
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice · 2020
No notice
28.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
29.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
30.
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication · 2020
Corrected
31.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
32.
Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease · 2020
No notice
33.
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease · 2020
No notice
34.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
35.
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity · 2020
No notice
36.
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters · 2020
No notice
37.
Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection · 2020
No notice
38.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
39.
This reference’s wording can’t be shown under the paper’s licence.
Not in our library
40.
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice · 2020
No notice

All 43 references

Cited by papers we hold 2

A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic · 2022
No notice
The SARS‐CoV‐2 main protease (M pro ): Structure, function, and emerging therapies for COVID‐19 · 2022
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.